Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer

Adults with pathologically confirmed lung cancer who are scheduled to receive first‐lineplatinum‐based chemotherapy are eligible. After providing written informed consent,participants are randomized 1:1 to receive either acupoint application using a herbalplaster applied to selected acupoints plus standard 5‐HT3 receptor antagonistprophylaxis, or 5‐HT3 receptor antagonist prophylaxis alone. Nausea and vomiting episodesare recorded by participants using patient diaries, and quality of life is assessed withthe Functional Living Index‐Emesis questionnaire.